Markets

Hims & Hers Health is trying to make weight loss cheaper—and turn telehealth into a front door

Date Published

Hims & Hers Health is trying to make weight loss cheaper—and turn telehealth into a front door

TL;DR

Quick Summary

  • On February 5, 2026, Hims announced a compounded semaglutide pill for weight loss with intro pricing starting at $49 for the first month (then standard $99/month, per company terms).
  • This is less about “beating” big pharma and more about owning the onboarding experience—cost + convenience + subscription follow-through.
  • Hims’ scale heading into 2026 matters: $586.0M revenue and 2.4M subscribers in Q1 2025; nearly $600M revenue and almost 2.5M subscribers by Q3 2025 (reported November 3, 2025).

#RealTalk

Hims is trying to turn the most in-demand category in healthcare into a consumer subscription—without getting trapped by the rules and optics that come with medicine.

Bottom Line

For investors, the story is whether Hims can keep expanding from “discreet prescriptions” into a broader, stickier health platform, while navigating compounding scrutiny and inevitable pushback from larger incumbents.

What happened today

On February 5, 2026, Hims & Hers Health, Inc. (HIMS) did the thing everyone in American healthcare talks about and almost nobody actually does: it tried to make a hot, high-demand drug category feel… normal-priced.

The company announced it will offer a compounded semaglutide pill as part of its weight loss program with introductory pricing starting at $49 for the first month on a multi-month plan, with standard pricing that the company says is $99 per month after the intro period. That’s a big contrast to brand-name pricing for Novo Nordisk’s newly launched oral Wegovy.

If you’re wondering why this matters beyond a single product: because Hims isn’t really selling “a pill.” It’s selling an experience—frictionless access, a subscription relationship, and a healthcare habit that starts on your phone.

The $49 moment is the business model in one screenshot

Hims has always been good at packaging uncomfortable or inconvenient health needs into something that looks and feels like modern consumer tech. Hair loss, ED, acne, anxiety—Hims made the pitch simple: click, consult, ship.

Weight loss is the biggest arena it’s entered yet, because GLP-1 demand has turned “metabolic health” into a mainstream shopping decision. For investors, Hims’ announcement is less about challenging Novo Nordisk in a head-to-head drug war (it can’t) and more about grabbing the top of the funnel.

Compounded medications aren’t FDA-approved, and Hims is explicit about that. But in real life, lots of consumers care about three things first: cost, access, and whether the process feels legit. Hims is betting its brand and onboarding can do what the traditional system still struggles with—get people from “I’m thinking about it” to “I’m on a plan” without a month of phone calls.

A telehealth company that wants to be your default

This isn’t happening in a vacuum. In 2025, Hims was already scaling fast.

In Q1 2025 (reported May 5, 2025), Hims reported revenue of $586.0 million and 2.4 million subscribers at quarter-end. It also reported net income of $49.5 million for that quarter. That’s not “cute little DTC brand” territory anymore; that’s real operating leverage showing up while the company’s still in growth mode.

And by Q3 2025 (reported November 3, 2025), revenue was nearly $600 million for the quarter, with subscribers up to almost 2.5 million.

So zoom out: Hims is trying to build the healthcare version of a consumer subscription platform—one where you start with one need and stick around because it’s convenient, private, and increasingly broad.

The bigger question: can Hims keep scaling without stepping on rakes?

Turning GLP-1-style weight loss into a subscription engine is a powerful narrative. But healthcare doesn’t let you move fast without consequences.

There are at least three pressure points investors should keep in mind going into 2026:

  • Regulatory and supply dynamics can change quickly, especially around compounding and shortages.
  • Competitive responses can be sharp when incumbents feel threatened—pricing programs, partnerships, and tighter distribution are all on the table.
  • Brand trust matters more in health than in most retail categories; one bad wave of headlines can be expensive.

Still, today’s move shows Hims understands the moment: consumers want healthcare that feels like modern commerce, and they want it at a price that doesn’t require a spreadsheet.

That’s the bet—Hims becomes the easiest place to start, and then the hardest place to leave.